Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has been given a consensus rating of “Moderate Buy” by the thirteen research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $26.5714.

KURA has been the subject of several research reports. Guggenheim assumed coverage on shares of Kura Oncology in a research report on Thursday, September 4th. They issued a “neutral” rating for the company. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Friday, November 14th. UBS Group upped their target price on shares of Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Finally, Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 5th.

Insider Buying and Selling

In other news, COO Kathleen Ford sold 6,902 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $77,164.36. Following the transaction, the chief operating officer owned 105,373 shares of the company’s stock, valued at approximately $1,178,070.14. The trade was a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian T. Powl sold 8,891 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $79,485.54. Following the sale, the insider owned 99,676 shares of the company’s stock, valued at $891,103.44. This trade represents a 8.19% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 122,675 shares of company stock worth $1,196,657. 6.40% of the stock is currently owned by insiders.

Institutional Trading of Kura Oncology

Hedge funds have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its holdings in Kura Oncology by 169.3% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 56,912 shares of the company’s stock valued at $334,000 after purchasing an additional 35,779 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Kura Oncology by 57.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,544,113 shares of the company’s stock valued at $10,191,000 after buying an additional 566,193 shares in the last quarter. Hsbc Holdings PLC grew its holdings in Kura Oncology by 26.5% during the first quarter. Hsbc Holdings PLC now owns 54,491 shares of the company’s stock worth $351,000 after acquiring an additional 11,406 shares during the period. Acadian Asset Management LLC purchased a new position in Kura Oncology in the first quarter worth $2,180,000. Finally, Los Angeles Capital Management LLC purchased a new position in Kura Oncology in the second quarter worth $450,000.

Kura Oncology Stock Down 2.3%

Shares of NASDAQ KURA opened at $10.22 on Monday. The business has a 50-day moving average price of $10.59 and a 200 day moving average price of $8.24. The stock has a market cap of $889.34 million, a PE ratio of -4.12 and a beta of 0.21. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $12.49.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The firm had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. Equities research analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.